Millennium Management
BEAM icon

Millennium Management’s Beam Therapeutics BEAM Stock Holding History

Millennium Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16,800
Closed -$800K – 6572
2022
Q3 		$800K Buy
+16,800
New +$958K ﹤0.01% 4529

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Millennium Management's BEAM Position: Q1 2026 in Review

Millennium Management reduced its Beam Therapeutics (BEAM) stake by 93% in Q1 2026, selling an estimated $7.75M and leaving 22,234 shares worth $530K. The position accounts for ﹤0.01% of the portfolio, ranked #4737.

Millennium Management first reported a position in BEAM in Q1 2020 and has held it in 24 quarters since. The position peaked at $33.1M in Q1 2022. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Millennium Management held 22,234 shares of Beam Therapeutics worth $530K as of Q1 2026.
  • Millennium Management sold 279,416 Beam Therapeutics shares in Q1 2026, an estimated $7.75M.
  • Beam Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4737 holding.
  • Millennium Management first reported a position in Beam Therapeutics in Q1 2020 and has held it in 24 quarters since.
  • Millennium Management's Beam Therapeutics position peaked at $33.1M in Q1 2022.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.